27 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Asthma
  • Immunotherapy
  • Product Initiative
  • Anergis SA

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Product Initiative
  • Anergis SA

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Asthma
  • United States
  • World
  • Product Initiative

PATIENTS WERE RANDOMIZED IN A ##:## FASHION TO ACTIVE DRUG VERSUS PLACEBO.

  • Allergy
  • Asthma
  • Immunotherapy
  • Sleep Aid
  • Therapy

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Immunotherapy
  • Therapy

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Asthma
  • Immunotherapy
  • United States
  • Product Initiative

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Chronic Disease
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Chronic Disease
  • Biomay AG

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy
  • Asthma
  • Pharmaceutical
  • Japan
  • Product Initiative

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Asthma
  • Chronic Disease
  • World
  • Product Initiative

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Asthma
  • Pharmaceutical
  • Japan
  • Product Initiative

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy
  • Asthma
  • Pharmaceutical
  • World
  • Product Initiative

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Allergy
  • Asthma
  • Pharmaceutical
  • World
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Asthma
  • Biotechnology
  • Medical Biotechnology
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy
  • Asthma
  • Ophthalmic Solution
  • Sleep Aid
  • Product Initiative

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Allergy
  • Antifungal
  • Asthma
  • Digestive System Disorder
  • Sleep Aid

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Allergy
  • Antifungal
  • Asthma
  • Digestive System Disorder
  • Sleep Aid

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy
  • Allergy Drug
  • Asthma
  • Eye Disease
  • Ophthalmic Solution

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Allergy
  • Asthma
  • Targeted Therapy
  • United States
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Allergy
  • Asthma
  • Respiratory Disease
  • Sleep Aid
  • Therapy

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Allergy
  • Asthma
  • Sleep Aid
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy
  • Asthma
  • Therapy
  • United States
  • Product Initiative

Efficacy was evaluated at Night ## (first drug administration) and after ## weeks of drug administration (Night ##).

  • Allergy
  • Asthma
  • Sleep Aid
  • Therapy
  • Eisai Co., Ltd.

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy
  • Asthma
  • Monoclonal Antibody
  • Respiratory Disease
  • Sleep Aid

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Allergy
  • Asthma
  • Respiratory Disease
  • Sleep Aid
  • Therapy

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Allergy
  • Antifungal
  • Monoclonal Antibody
  • United States
  • SCYNEXIS, Inc.

CY-## - DRUG PROFILE DORA-## - DRUG PROFILE DRGT-## - DRUG PROFILE DRUG FOR INSOMNIA - DRUG PROFILE DRUGS TO INHIBIT ANGIOTENSIN II RECEPTOR TYPE ## FOR INSOMNIA - DRUG PROFILE EVT-## - DRUG PROFILE Drug Name C

  • Allergy
  • Asthma
  • Sleep Aid
  • Therapy
  • United States